Johan Sebregts

Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom.

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Thuja Capital Management BV is a Venture Capital firm, a subsidiary of Thuja Capital Holding BV founded in 2006 by Harrold van Barlingen. Thuja Capital Management BV is headquartered in Utrecht.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Smith Kline & French Laboratories Ltd. manufactures pharmaceutical products. The company is headquartered in Brentford, the United Kingdom.

INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam.

Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom.

Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom.

Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019.

Phlox Therapeutics BV is a Dutch company that develops gene therapy to alleviate and cure cardiomyopathies. The company is based in Naarden, Netherlands. The company was founded by Yigal M. Pinto, Eva van Rooijen.